
FDA Approves Moderna RSV Vaccine, an mRNA Alternative to GSK and Pfizer Products
Moderna’s mRNA vaccine for RSV has been FDA approved for adults 60 and older, marketed as mResvia. The vaccine is expected to be available before the 2024/2025 respiratory virus season. It is based on prefusion F protein technology, showing 78.7% efficacy in initial studies. Compared to GSK and Pfizer’s RSV vaccines, mResvia is administered via…